{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:25:47Z","timestamp":1779931547978,"version":"3.53.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05584-7","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T03:37:27Z","timestamp":1743478647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a decision analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Luca","family":"Afferi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar H.","family":"Kelkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijntje W.","family":"Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zach M.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian D.","family":"Fankhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"issue":"1","key":"5584_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. Cancer J Clin 74(1):12\u201349","journal-title":"Cancer J Clin"},{"issue":"22","key":"5584_CR2","first-page":"00173","volume":"S2588\u20139311","author":"N Lobo","year":"2022","unstructured":"Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP et al (2022) Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol S2588\u20139311(22):00173\u201300170","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"5584_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"CL Vale","year":"2005","unstructured":"Vale CL (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and Meta-Analysis of individual patient data: advanced bladder cancer (ABC) Meta-analysis collaboration. Eur Urol 48(2):202\u2013206","journal-title":"Eur Urol"},{"key":"5584_CR4","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA et al European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. European Urology [Internet]. 2023 Oct 17 [cited 2023 Nov 7]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0302283823030737"},{"issue":"1","key":"5584_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","volume":"81","author":"Advanced Bladder Cancer (ABC)","year":"2022","unstructured":"Advanced Bladder Cancer (ABC) (2022) Meta-analysis collaborators group. Adjuvant chemotherapy for Muscle-invasive bladder cancer: A systematic review and Meta-analysis of individual participant data from randomised controlled trials. Eur Urol 81(1):50\u201361","journal-title":"Eur Urol"},{"issue":"1","key":"5584_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT et al (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66(1):42\u201354","journal-title":"Eur Urol"},{"issue":"4","key":"5584_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2003.05.101","volume":"21","author":"S Madersbacher","year":"2003","unstructured":"Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R et al (2003) Radical cystectomy for bladder cancer Today\u2014A homogeneous series without neoadjuvant therapy. JCO 21(4):690\u2013696","journal-title":"JCO"},{"issue":"24","key":"5584_CR8","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1002\/cncr.34502","volume":"128","author":"DD Joyce","year":"2022","unstructured":"Joyce DD, Wymer KM, Sharma V, Moriarty JP, Borah BJ, Geynisman DM et al (2022) Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: results according to VESPER data. Cancer 128(24):4194\u20134202","journal-title":"Cancer"},{"issue":"2","key":"5584_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.eururo.2008.10.016","volume":"55","author":"F Calabr\u00f2","year":"2009","unstructured":"Calabr\u00f2 F, Sternberg CN (2009) Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 55(2):348\u2013358","journal-title":"Eur Urol"},{"issue":"10","key":"5584_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M et al (2016) Recommendations for conduct, methodological practices, and reporting of Cost-effectiveness analyses: second panel on Cost-Effectiveness in health and medicine. JAMA 316(10):1093\u20131103","journal-title":"JAMA"},{"issue":"9","key":"5584_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC (2014) Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371(9):796\u2013797","journal-title":"N Engl J Med"},{"key":"5584_CR12","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N National Comprehensive Cancer Network Guidelines Version 1.2024 on bladder cancer [Internet]. NCCN. [cited 2024 Feb 16]. Available from: https:\/\/www.nccn.org\/guidelines\/recently-published-guidelines"},{"issue":"2","key":"5584_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bju.14872","volume":"125","author":"A Martini","year":"2020","unstructured":"Martini A, Sfakianos JP, Renstr\u00f6m-Koskela L, Mortezavi A, Falagario UG, Egevad L et al (2020) The natural history of untreated muscle-invasive bladder cancer. BJU Int 125(2):270\u2013275","journal-title":"BJU Int"},{"issue":"3","key":"5584_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0022-5347(17)38368-4","volume":"145","author":"DG Skinner","year":"1991","unstructured":"Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P et al (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145(3):459\u2013464 discussion 464\u2013467","journal-title":"J Urol"},{"issue":"21","key":"5584_CR15","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21):4602\u20134608","journal-title":"J Clin Oncol"},{"issue":"11","key":"5584_CR16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L et al (2017) Pembrolizumab as Second-Line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026","journal-title":"N Engl J Med"},{"key":"5584_CR17","doi-asserted-by":"publisher","unstructured":"Xie Q, Zheng H, Chen Y, Peng X Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma. Front Public Health [Internet]. 2022 Apr 27 [cited 2024 Apr 18];10. Available from: https:\/\/www.frontiersin.org\/journals\/public-health\/articles\/https:\/\/doi.org\/10.3389\/fpubh.2022.837854\/full","DOI":"10.3389\/fpubh.2022.837854\/full"},{"key":"5584_CR18","unstructured":"Arias E, Xu J (2019) United States life tables, National Center for Health Statistics (U.S.), editor. 2022;70(19). Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/113096"},{"issue":"6","key":"5584_CR19","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.euf.2018.04.014","volume":"5","author":"CTJ Michels","year":"2019","unstructured":"Michels CTJ, Wijburg CJ, Leijte E, Witjes JA, Rovers MM, Grutters JPC (2019) A cost-effectiveness modeling study of robot-assisted (RARC) versus open radical cystectomy (ORC) for bladder cancer to inform future research. Eur Urol Focus 5(6):1058\u20131065","journal-title":"Eur Urol Focus"},{"issue":"1","key":"5584_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000524578","volume":"107","author":"F Korkes","year":"2023","unstructured":"Korkes F, Timoteo F, Baccaglini W, Glina F, Faba OR, Palou Redorta J et al (2023) Postoperative mortality rate after radical cystectomy: A systematic review of epidemiologic series. Urol Int 107(1):96\u2013104","journal-title":"Urol Int"},{"issue":"2","key":"5584_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"C Pfister","year":"2021","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, Souli\u00e9 M, Guy L, Laguerre B et al (2021) Randomized phase III trial of Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with Muscle-invasive bladder cancer. Analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol 79(2):214\u2013221","journal-title":"Eur Urol"},{"issue":"11","key":"5584_CR22","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, Grivas P, Vuky J, Powles T et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(11):1483\u20131492","journal-title":"Lancet Oncol"},{"issue":"25","key":"5584_CR23","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","volume":"52","author":"DJ Cohen","year":"2008","unstructured":"Cohen DJ, Reynolds MR (2008) Interpreting the results of Cost-Effectiveness studies. J Am Coll Cardiol 52(25):2119\u20132126","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"5584_CR24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB et al (2012) Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task Force-7. Med Decis Mak 32(5):733\u2013743","journal-title":"Med Decis Mak"},{"key":"5584_CR25","doi-asserted-by":"crossref","unstructured":"Afferi L, Zamboni S, Karnes RJ, Roghmann F, Sargos P, Montorsi F et al (2020) The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. World J Urol 39(2):443\u2013451","DOI":"10.1007\/s00345-020-03205-z"},{"issue":"3","key":"5584_CR26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.euo.2021.01.005","volume":"5","author":"CS Voskuilen","year":"2022","unstructured":"Voskuilen CS, van Gennep EJ, Einerhand SMH, Vegt E, Donswijk ML, Bruining A et al (2022) Staging 18F-fluorodeoxyglucose positron emission tomography\/computed tomography changes treatment recommendation in invasive bladder cancer. Eur Urol Oncol 5(3):366\u2013369","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"5584_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.eururo.2022.07.023","volume":"83","author":"A Gil-Jimenez","year":"2023","unstructured":"Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis DJ, Braaf L et al (2023) Assessment of predictive genomic biomarkers for response to Cisplatin-based neoadjuvant chemotherapy in bladder cancer. Eur Urol 83(4):313\u2013317","journal-title":"Eur Urol"},{"key":"5584_CR28","doi-asserted-by":"crossref","unstructured":"Afferi L, Lonati C, Montorsi F, Briganti A, Necchi A, Mari A et al (2022) Selecting the best candidates for Cisplatin-based adjuvant chemotherapy after radical cystectomy among patients with pN\u2009+\u2009Bladder cancer. Eur Urol Oncol 5(6):722\u2013725","DOI":"10.1016\/j.euo.2022.04.001"},{"issue":"22","key":"5584_CR29","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y et al (2021) Adjuvant nivolumab versus placebo in Muscle-Invasive urothelial carcinoma. N Engl J Med 384(22):2102\u20132114","journal-title":"N Engl J Med"},{"issue":"8","key":"5584_CR30","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA et al (2022) NCCN guidelines\u00ae insights: bladder cancer, version 2.2022: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 20(8):866\u2013878","journal-title":"J Natl Compr Canc Netw"},{"key":"5584_CR31","doi-asserted-by":"crossref","unstructured":"Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H et al (2024) Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin\/gemcitabine. BJU Int 134(3):388\u2013397","DOI":"10.1111\/bju.16318"},{"issue":"6","key":"5584_CR32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.eururo.2024.01.007","volume":"85","author":"JE Rosenberg","year":"2024","unstructured":"Rosenberg JE, Mamtani R, Sonpavde GP, Loriot Y, Duran I, Lee JL et al (2024) Health-related quality of life in patients with previously treated advanced urothelial carcinoma from EV-301: A phase 3 trial of enfortumab Vedotin versus chemotherapy. Eur Urol 85(6):574\u2013585","journal-title":"Eur Urol"},{"issue":"3","key":"5584_CR33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.22031","volume":"107","author":"A Dash","year":"2006","unstructured":"Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107(3):506\u2013513","journal-title":"Cancer"},{"issue":"10","key":"5584_CR34","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","volume":"30","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G et al (2012) Randomized phase III study comparing Paclitaxel\/Cisplatin\/ gemcitabine and gemcitabine\/Cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. JCO 30(10):1107\u20131113","journal-title":"JCO"},{"issue":"7","key":"5584_CR35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, Matsubara N, G\u00e9czi L, Cheng SYS et al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22(7):931\u2013945","journal-title":"Lancet Oncol"},{"issue":"8","key":"5584_CR36","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.urolonc.2014.05.001","volume":"32","author":"SM Stevenson","year":"2014","unstructured":"Stevenson SM, Danzig MR, Ghandour RA, Deibert CM, Decastro GJ, Benson MC et al (2014) Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. Urol Oncol 32(8):1172\u20131177","journal-title":"Urol Oncol"},{"issue":"5","key":"5584_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.euo.2018.09.012","volume":"3","author":"T Srivastava","year":"2020","unstructured":"Srivastava T, Prabhu VS, Li H, Xu R, Zarabi N, Zhong Y et al (2020) Cost-effectiveness of pembrolizumab as Second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden. Eur Urol Oncol 3(5):663\u2013670","journal-title":"Eur Urol Oncol"},{"issue":"23","key":"5584_CR38","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1002\/cncr.24634","volume":"115","author":"GS Kulkarni","year":"2009","unstructured":"Kulkarni GS, Alibhai SMH, Finelli A, Fleshner NE, Jewett MAS, Lopushinsky SR et al (2009) Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 115(23):5450\u20135459","journal-title":"Cancer"},{"issue":"9","key":"5584_CR39","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","volume":"4","author":"GS Kulkarni","year":"2007","unstructured":"Kulkarni GS, Finelli A, Fleshner NE, Jewett MAS, Lopushinsky SR, Alibhai SMH (2007) Optimal management of High-Risk T1G3 bladder cancer: A decision analysis. PLoS Med 4(9):e284","journal-title":"PLoS Med"},{"key":"5584_CR40","doi-asserted-by":"publisher","unstructured":"Nam J, Milenkovski R, Yunger S, Geirnaert M, Paulson K, Seftel M (2018) Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. Journal of Medical Economics [Internet]. Jan 2 [cited 2024 Apr 18]; Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1080\/13696998.2017.1372230","DOI":"10.1080\/13696998.2017.1372230"},{"issue":"1","key":"5584_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.eururo.2018.03.006","volume":"74","author":"M Sarfaty","year":"2018","unstructured":"Sarfaty M, Hall PS, Chan KKW, Virik K, Leshno M, Gordon N et al (2018) Cost-effectiveness of pembrolizumab in Second-line advanced bladder cancer. Eur Urol 74(1):57\u201362","journal-title":"Eur Urol"},{"issue":"1","key":"5584_CR42","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.clgc.2020.07.006","volume":"19","author":"O Hale","year":"2021","unstructured":"Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL et al (2021) Cost-effectiveness of pembrolizumab versus Carboplatin-based chemotherapy as First-line treatment of PD-L1\u2013positive locally advanced or metastatic urothelial carcinoma ineligible for Cisplatin-based therapy in the united States. Clin Genitourin Cancer 19(1):e17\u201330","journal-title":"Clin Genitourin Cancer"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05584-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05584-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05584-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:53:40Z","timestamp":1767966820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05584-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5584"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05584-7","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,30]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}